Business Context and Reporting Period
This Form 8-K Current Report was filed by 180 Life Sciences Corp. (not Forum Markets Inc.) on May 27, 2021. The registrant is a Delaware corporation with principal executive offices in Menlo Park, CA. The report primarily addresses corporate governance changes, specifically the appointment of new directors and amendments to executive employment agreements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on non-financial operational events and compensation arrangements rather than periodic financial performance.
Material Changes and Corporate Actions
- Board Appointments: The Board appointed Russell T. Ray, MBA and Teresa DeLuca, MD, MBA as independent directors to fill two vacancies. The appointments are effective June 15, 2021.
- Director Compensation:
- Initial Option Grant: Each appointee received options to purchase shares with a value of $425,000 (determined via Black-Scholes). If the grant results in fewer than 100,000 shares, the difference is expected to be granted in the next compensation year.
- Vesting: Options vest monthly (1/48th of the balance per month). If the 100,000-share threshold adjustment applies, vesting is 1/36th per month.
- Cash Fees: Annual retainer of $40,000. Additional committee fees range from $5,000 to $15,000 depending on the committee and chairperson role.
- Executive Employment Amendment: A Second Amendment to the Employment Agreement with Interim CFO Ozan Pamir was executed on May 27, 2021. The amendment clarifies that all compensation payable to Mr. Pamir will be paid directly by 180 Life Sciences Corp.
- Unregistered Securities: The Initial Option Grants were issued pursuant to Section 4(a)(2) and/or Rule 506 of Regulation D exemptions, as they were not public offerings and were sold to accredited investors.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, forward-looking revenue projections, or specific risk factors beyond standard legal disclosures regarding unregistered securities. The Board determined that both new directors are "independent" under NASDAQ Capital Market rules. No specific committee assignments have been finalized for the new directors at the time of filing.
Investor Verification Checklist
- Verify the exact number of shares included in the $425,000 option grants based on the closing stock price on the grant date.
- Confirm the specific committee assignments for Russell T. Ray and Teresa DeLuca once determined by the Board.
- Review the full text of the "Form of Director Nominee Offer Letter" (Exhibit 10.1) for complete compensation terms.
- Monitor future filings for the issuance of the additional shares if the initial grant falls short of the 100,000-share threshold.